drugset / Trial / NCT00670319

Comparison of Raloxifene Hydrochloride and Placebo in the Treatment of Postmenopausal Women With Osteoporosis

NCT00670319

Phase 3 Completed 7705 enrolled Eli Lilly and Company
RandomizedParallel-groupTriple-blindTreatment

Summary

To study the effect of long-term treatment with raloxifene, compared with placebo, on the rate of new vertebral fractures in osteoporotic postmenopausal women with and without existing vertebral fractures.

Timeline

Start
1994-11
Primary completion
1999-09
Completion
1999-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Raloxifene Other / unclassified 60 mg Oral
Subject Raloxifene Other / unclassified 120 mg Oral